EndoGastric Solutions secured additional financing of up to $50 million.
Here are four key notes:
1. CRG and existing EndoGastric Solutions’ investors led the financing round.
2. The company plans to use proceeds from the financing to begin broad-scale commercialization as well as making further R&D investments in next generation products used in its proprietary TIF procedure.
3. The Transoral Incisionless Fundoplication procedure offers patients who require an anatomical repair another treatment option to correct the underlying cause of GERD.
4. The Federal Register recently posted coding and payment information for the new CPT code covering the TIF procedures from EndoGastric Solutions.